Waheed Nadia 4
4 · OCULAR THERAPEUTIX, INC · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
OCULAR THERAPEUTIX (OCUL) CMO Nadia Waheed Sells 7,863 Shares
What Happened Nadia Waheed, Chief Medical Officer of Ocular Therapeutix (OCUL), disposed of 7,863 shares on 2026-02-12 in an open-market sale. The weighted-average price was $9.04 per share, producing gross proceeds of roughly $71,082. The sale was a sell-to-cover tied to the vesting of restricted stock units (RSUs) and was executed under a pre-established automatic instruction rather than as a discretionary trade.
Key Details
- Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (filed late relative to the 2-business-day rule).
- Shares sold: 7,863; weighted-average price: $9.04; proceeds ≈ $71,082.
- Price range: $8.9950 to $9.0840 across multiple executions (report lists weighted average; reporter will provide per-price breakdown upon request).
- Reason/footnote: Sell-to-cover to satisfy tax withholding for RSUs that vested on February 11, 2026; implemented via a durable automatic sale instruction adopted June 1, 2024 (not a discretionary trade).
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
Context Sell-to-cover transactions to satisfy tax withholding on vested RSUs are common and typically considered routine administrative sales rather than a statement of confidence or lack thereof. The late filing reduces immediate disclosure transparency and may be noted by investors, but the footnotes indicate this was an automatic, non-discretionary tax withholding sale.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-12$9.04/sh−7,863$71,082→ 318,417 total
Footnotes (2)
- [F1]Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on June 1, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.9950 to $9.0840, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.